Biotech’s Best in Boston: BIO International 2018
This week, Boston plays host to a biotech audience of more than 15,000 people at the 2018 BIO International Convention. The convention, held at the Boston Convention and Exhibition Center from June 4-7, brings professionals from 1,100 biotechnology companies, state organizations, and academic institutions together in one location to network and discuss advances in the industry. Stem cell research, drug discovery and development, and nanotechnology are just a few of the areas that will be focused on at the event. The goal of the event is to foster interdisciplinary research and collaboration in the life sciences industry.
There is always a real energy at BIO 2018, with this year being no exception. Several speakers and panelists are referencing recent advances in cell culture therapies, including the first ever approval by the FDA for a CAR-T cell therapy, Kymriah by Novartis. Life science leadership at Novartis, Pfizer, and other major biotech institutions spoke of a fundamental shift toward the patient, as the quality of outcomes and the personalization of medicine become guiding philosophies in life science. CRISPR gene editing, CAR-T cell culture therapies, and other advances bring the promise of effective treatments to a known pool of common diseases. Pharma will be checking these off, one-by-one, in the decade to come.
We are excited to see what the next two days of the conference bring for the future of biotech! For more information, visit: http://convention.bio.org/home.aspx